Role of monocarboxylate transporters and glucose transporters in prostate cancer

• Published in: Urologia 2023-08, Vol.90 (3), p.491-498
• Main Authors: Vovdenko, Stanislav, Morozov, Andrey, Ali, Stanislav, Kogan, Evgeniia, Bezrukov, Evgeny
• Format: Article
• Language: English
• ISSN: 0391-5603; 1724-6075
• DOI: 10.1177/03915603221111125

Objectives: Currently, research of new diagnostic approaches to detect clinically significant prostate cancer is relevant because of the importance of early detection of aggressive forms of the disease, often challenging, even when using modern diagnostic tools. The aim of this review is to present the current knowledge regarding monocarboxylate transporters’ and glucose transporters’ expression as a component of glycolytic phenotype definition in prostate cancer cells. Methods: We searched PubMed and Scopus databases. Twenty-six articles from 2003 to 2022 were included. Literature research and selection were carried out based on the recommendations of the PRISMA statement. Results: The presence of “lactate shuttle” in the tumor tissue is associated with a worse prognosis. Increased expression of MCT2, MCT4, GLUT1, and down-regulation of GLUT3 are associated with prostate adenocarcinoma. MCT4 expression level correlates with the grade of tumor malignancy and disease prognosis. Up-regulation of GLUT1 and MCT4 is typical for hormone-resistant prostate cancer. Inhibition of MCT1 and MCT4 and GLUT1 in prostate cancer cells reduces their metabolic activity and growth rate, a suitable novel approach for targeted therapy. Conclusion: Review of the current studies showed that expression of certain MCTs and GLUTs types are associated with prostate cancer and some of them correlate with high malignancy and poor prognosis. Detection by immunohistochemistry of these transporters could represent a new diagnostic tool to identify aggressive forms of prostate cancer, and a novel therapeutic target for selective drugs.